REG - SkinBioTherapeutics - FY Trading Update

SkinbiotherapeuticsAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250814:nRSN2573Va&default-theme=true

RNS Number : 2573V  SkinBioTherapeutics PLC  14 August 2025

SkinBioTherapeutics plc
("SkinBioTherapeutics" or the "Group" or the "Company")

FY Trading Update

14 August 2025 - SkinBioTherapeutics plc (AIM: SBTX), a life science group
focused on skin health, announces its trading update for the 12 months to 30
June 2025 (FY25).

Management expects to report unaudited revenues of between c.£4.5m-£4.8m(1)
(FY24: £1.2m),  driven by a full year's trading by Dermatonics, eight months
trading by Bio-Tech Solutions (BTS), as well as ongoing growth of organic
sales of AxisBiotix. Revenues were slightly lower than market expectations due
to timing of orders for Dermatonics and BTS, much of which occurred just after
the year end.

Management expects unaudited adjusted EBITDA loss of between c.£0.2m-
£0.4m(1) (FY24: loss £2.2m) due to careful cost control.

Cash as at 30 June 2025 is better than expectations at £4.8m(1) (31 Dec 2024:
£1.2m) reflecting the June 2025 Placing and WRAP Retail Offer of £4.2m
(gross) to support the exclusive commercial agreement with Superdrug Stores
plc
(https://irs.nbtrader.co.uk/ir/SkinBiotix/newsArticle.php?id=311428254081056341&ST=SBTX)
('Superdrug') related to AxisBiotix™ food supplements. Prior to the year-end
the Company began incurring costs in preparation for the initial Superdrug
launch; the cash at the period end reflects this expenditure.

The above figures are subject to review by the Company's auditors before
publication of the final FY25 results later in the year.

Post year end, July was a strong month with significant orders and good
trading across the board, especially for the BTS business. Operationally, the
team is busy preparing for the launch of AxisBiotix™ in Superdrug stores in
the Autumn and is on track.

SkinBioTherapeutics records its revenues under regulatory accounting rule FRS
102 and will continue to segment it geographically as before in its published
accounts. Given the competitiveness of the industries that SkinBioTherapeutics
operates in, the Company will not divulge information on individual customer
sales or provide guidance beyond what is required by disclosure rules.
Shareholders are respectfully requested not to contact the Company's customers
or partners for additional information as it may harm ongoing and future
relationships.

Stuart Ashman, CEO of SkinBioTherapeutics plc, said:

"The past 12 months have marked a distinct change in the operations of the
Company, driven by two acquisitions, the launch of Zenakine™ by Croda and
the signing of a significant commercial deal with Superdrug to launch
AxisBiotix™ on the UK high street. Financially, we are also in a very
different place, achieving c.4x the revenues relative to 2024, nearing
profitability and have a strong cash balance. Compared to where we were only
five years ago, where our majority focus was around research and development,
we have come a long way. We strongly believe that the increased interest by
consumers and the marketplace in the role of the microbiome on our skin health
means that we are very well placed to scale rapidly and achieve significant
value for shareholders."

The Company will be reporting its full year results later in the year and will
hold a presentation for shareholders at that time. In the meantime, it will
report any material information and information of potential interest to
shareholders via the RNS system. For information on its operations and
products, please visit the individual websites, Dermatonics
(https://www.dermatonics.co.uk/) , Bio-Tech Solutions
(https://www.btsl.uk.com/)  and AxisBiotix (http://www.axisbiotix.com)  or
the Company's LinkedIn HERE
(https://www.linkedin.com/company/22286644/admin/dashboard/) .

Footnote

1.   The Company considers market expectations prior to the release of this
announcement for the year ending 30 June 2025 to be revenue of £5.1m,
Adjusted EBITDA of £0.3m loss and cash of £4.1m.

-Ends-

For more information please contact:

 SkinBioTherapeutics plc                                  +44 (0) 191 495 7325

 Stuart J. Ashman, CEO

Simon Hewitson, COO

 Singer Capital Markets (Nominated Adviser & Broker)      +44 (0) 020 7496 3000

 Philip Davies

 Sam Butcher

 Patrick Weaver

 Vigo Consulting (financial press)                        +44 (0) 20 7390 0230

 Rozi Morris                                              SkinBio@vigoconsulting.com

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The
Group's proprietary platform technology, SkinBiotix®, is based upon
discoveries made by the translational dermatology team at the University of
Manchester.

The Group's foundation business is targeting the skin healthcare market via
five pillars, the most advanced of which are cosmetic skincare (SkinBiotix)
and food supplements that harness the gut-skin axis (AxisBiotix). The cosmetic
pillar has a partnership with Croda plc and the Group's first in-house
product, AxisBiotix-Ps™, a food supplement to alleviate the symptoms of
inflammatory skin conditions, is sold directly and via Amazon, and will be
sold via an exclusive UK commercial deal with Superdrug Stores plc later in
2025.

The Group is also acting as a consolidator and is making acquisitions in
complementary areas such as skin care and cosmetic applications, that also
bring new distribution and geographical platforms, and manufacturing
capabilities through which it can funnel its in-house pillar products.

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For
more information, visit: www.skinbiotherapeutics.com
(http://www.skinbiotherapeutics.com) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTDGGDISGBDGUX